1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

26 Nov 2021
Admin
News Article

Novartis Receives Fda Breakthrough Therapy Designation For Rare Disease Med

Swiss Pharma Company Novartis Has Received A Breakthrough Therapy Designation (Btd) For Its Experimental Medication Iptacopan For The Rare Blood Disorder Paroxysmal Nocturnal Hemoglobinuria (Pnh).The Therapy, Also Known As Lnp023, Was Also Awarded A Rare Paediatric Disease Designation At The Same Time For The Treatment Of C3 Glomerulopathy (C3G), A Group Of Ultra Rare Conditions That Can Cause End-Stage Renal Disease.Iptacopan Is An Oral Factor B Inhibitor And Is In Development Not Only For Pnh And C3G, But Also A Number Of Other Renal Conditions With Complement System Involvement.This Includes Iga Nephropathy (Igan), Atypical Hemolytic Uremic Syndrome (Ahus), And Membranous Nephropathy (Mn).The Btd Designation Was Based On The Positive Interim Results From Two Ongoing Phase 2 Studies, Within Which Iptacopan Demonstrated Benefits In Patients Who Remained Anaemic And Dependent On Transfusions, Despite Standard Of Care Anti-Complement Treatment, As Well As Monotherapy In Anti-C5 Naive Pnh Patients.In This Study, Iptacopan Significantly Reduced Proteinuria

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!